Skip to main content

Table 1 The clinical course of the patient

From: De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome

Time

Management process

d1

(3/20)

Diagnosis established;

Induction chemotherapy consisting of homoharringtonine, cytarabine and daunorubicin began.

d30

Bone marrow smear showed 20.4% megakaryoblasts and 24.8% promegakaryocytes (chemotherapy failure);

Second induction chemotherapy.

d60

Bone marrow smear showed 6% megakaryoblasts and 11% promegakaryocytes (partial remission);

Imatinib treatment started (600 mg/d) and CAG regimen

d67

WBC: 3.5 × 109/L.

d69

Imatinib reduced to 400 mg/d.

d75

Imatinib discontinued (WBC: 0.9 × 109/L).

d102

Imatinib restarted (200 mg/d);

WBC: 4.3 × 10 9 /L (d106)

d107

Imatinib increased to 400 mg/d

d110: complete hematological remission

WBC:3.2 × 109/L (d110); 3.5 × 109/L (d120); 4.2 × 109/L (d130)

d132

Imatinib discontinued (due to financial reasons)

d150

Relapse.

d177

Patient deceased.

  1. Abbreviations: d, day; CAG regimen: cytarabine 30 mg/day for 14 days, aclarubicin 10 mg/day on days 1 - 8, and granulocyte colony-stimulating factor 300 μg/day on days 1 - 14; WBC, white blood cell count.